• Disease
  • Gynecologic
  • Gynecologic Oncology
  • Joel I Sorosky

    Prominent publications by JOEL I SOROSKY

    KOL Index score: 17632

    PURPOSE: Intensity-modulated radiotherapy (IMRT) has been shown to reduce the radiation dose to small bowel in pelvic RT in gynecology patients. Prone positioning has also been used to decrease small bowel dose by displacement of small bowel from the RT field in these patients. The purpose of this study was to determine whether the combination of both IMRT and prone positioning on a belly board can reduce small bowel dose further in gynecologic cancer patients undergoing pelvic ...

    Also Ranks for: Small Bowel |  gynecologic cancer |  pelvic radiation |  belly board |  prone positioning
    KOL Index score: 14800

    PURPOSE: Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody.

    PATIENTS AND METHODS: Eligible patients had persistent or recurrent EOC/PPC after one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of ...

    Also Ranks for: Gynecologic Oncology |  epithelial ovarian |  primary peritoneal cancer |  local neoplasms |  monoclonal antibodies
    KOL Index score: 14334

    PURPOSE: Recently, imaging-based tumor volume before, during, and after radiation therapy (RT) has been shown to predict tumor response in cervical cancer. However, the effectiveness of different methods and timing of imaging-based tumor size assessment have not been investigated. The purpose of this study was to compare the predictive value for treatment outcome derived from simple diameter-based ellipsoid tumor volume measurement using orthogonal diameters (with ellipsoid computation) ...

    Also Ranks for: Magnetic Resonance |  cervical cancer |  outcome prediction |  tumor volume |  local control
    KOL Index score: 14324

    OBJECTIVE: The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival. Secondarily, we sought to determine the toxicity of ifosfamide-cisplatin in this patient population.

    METHODS: Patients were randomized to receive ifosfamide (1.5 g/m(2)/day) times 5 ...

    Also Ranks for: Gynecologic Oncology |  ifosfamide cisplatin |  antineoplastic agents |  phase iii trial |  progressionfree survival
    KOL Index score: 14036

    PURPOSE: This study investigated sequential changes in tumor blood supply using magnetic resonance (MR) perfusion imaging and assessed their significance in the prediction of outcome of patients with advanced cervical cancer. The purpose of this project was to devise a simple, noninvasive method to predict early signs of treatment failure in advanced cervical cancer treated with conventional radiation therapy.

    METHODS AND MATERIALS: Sixty-eight MR perfusion studies were performed ...

    Also Ranks for: Tumor Perfusion |  magnetic resonance |  advanced cervical cancer |  radiation therapy |  2 weeks
    KOL Index score: 13292

    PURPOSE: On the basis of reported activity of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or topotecan plus cisplatin in advanced cervix cancer, we undertook a randomized trial comparing these combinations versus cisplatin alone, to determine whether survival is improved with either combination compared with cisplatin alone, and to compare toxicities and quality of life (QOL) among the regimens.

    PATIENTS AND METHODS: Eligible patients were randomly allocated to receive ...

    Also Ranks for: Uterine Cervix |  cisplatin topotecan |  phase iii |  gynecologic oncology |  aged antineoplastic
    KOL Index score: 12805

    BACKGROUND: Traditional inguinal lymphadenectomy includes the removal of a portion of the saphenous vein. The authors hypothesized that preserving the saphenous vein would decrease morbidity without affecting treatment outcome.

    METHODS: A retrospective review of 83 patients with carcinoma of the vulva who underwent inguinal lymphadenectomy between 1990-1998 was performed. Postoperative short term and long term complications were evaluated.

    RESULTS: A total of 139 inguinal dissections ...

    Also Ranks for: Saphenous Vein |  inguinal lymphadenectomy |  carcinoma vulva |  morbidity patients |  term complications
    KOL Index score: 12052

    OBJECTIVE: We sought to estimate the rates and types of evaluation in women with atypical glandular cells of undetermined significance (AGC-US) on cervical cytology and to assess these findings on the basis of published management guidelines.

    METHODS: The rates of histologic sampling, comprehensive initial evaluations, and secondary evaluations were assessed in 477 women with an AGC-US Pap test from 1998 to 2001. A comprehensive evaluation was defined as a colposcopy and an endocervical ...

    Also Ranks for: Cervical Cytology |  practice guidelines |  comprehensive evaluation |  women agc |  atypical glandular
    KOL Index score: 11760

    PURPOSE: Clinical evaluation of tumor size in cervical cancer is often difficult, and clinical signs of radiation therapy failure may not be present until well after completion of treatment. The purpose of this study is to investigate early indicators of treatment response using magnetic resonance (MR) imaging for quantitative assessment of tumor volume and tumor regression rate before, during, and after radiation therapy.

    METHODS AND MATERIALS: Thirty-four patients with cervical cancer ...

    Also Ranks for: Radiation Therapy |  magnetic resonance |  tumor volume |  uterine cervix |  aged neoplasm
    KOL Index score: 11677

    PURPOSE: Psychosocial stress has been related to impaired immunity in cancer patients. However, the extent to which these relationships exist in immune cells in the tumor microenvironment in humans has not been explored. We examined relationships among distress, social support, and natural killer (NK) cell activity in ovarian cancer patients in peripheral-blood mononuclear cells (PBMC), ascitic fluid, and tumor-infiltrating lymphocytes (TIL).

    PATIENTS AND METHODS: Patients awaiting ...

    Also Ranks for: Social Support |  psychological distress |  ovarian cancer |  natural killer |  cell activity
    KOL Index score: 11206

    BACKGROUND: This study was performed to determine whether 24-h paclitaxel plus doxorubicin and filgrastim was superior to cisplatin plus doxorubicin in patients with endometrial cancer with respect to response, progression-free survival (PFS) and overall survival (OS).

    PATIENTS AND METHODS: Eligible chemotherapy-naïve patients were randomly assigned to doxorubicin 60 mg/m2 intravenously (i.v.) followed by cisplatin 50 mg/m2 i.v. (arm 1, n=157) or doxorubicin 50 mg/m2 i.v. followed 4 h ...

    Also Ranks for: Endometrial Carcinoma |  gynecologic oncology |  doxorubicin cisplatin |  phase iii |  aged paclitaxel
    KOL Index score: 11012

    PURPOSE: Tumor size estimated by pelvic examination (PE) is an important prognostic factor in cervical cancer treated with radiation therapy (RT). Recent histologic correlation studies also showed that magnetic resonance (MR) imaging provides highly accurate measurements of the actual tumor volume. The purpose of this study was to: (a) compare the accuracy of PE and MR in predicting outcome, and (b) correlate tumor measurements by PE versus MR.

    METHODS AND MATERIALS: Tumor measurements ...

    Also Ranks for: Tumor Size |  cervical cancer |  pelvic examination |  local control |  prediction outcome
    KOL Index score: 10478

    OBJECTIVES: The Gynecologic Oncology Group (GOG) compared methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with topotecan and cisplatin (TC) or cisplatin alone (C) in advanced cervical cancer. The primary endpoint was overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL) as secondary objectives.

    METHODS: Eligible patients were randomly allocated to receive either cisplatin 50 mg/m2 q 3 weeks (C) or cisplatin 50 mg/m2 day 1 and ...

    Also Ranks for: Gynecologic Oncology |  quality life |  uterine cervix |  advanced cervical cancer |  progressionfree survival


    JOEL I SOROSKY: Influence Statistics

    Sample of concepts for which JOEL I SOROSKY is among the top experts in the world.
    Concept World rank
    cis pregnancy #1
    leiomyoma broad #1
    citrate pelvic #1
    initial agc #1
    52 malignancy #1
    malignancy cervix #1
    mme shorter length #1
    cervical biopsy women #1
    clinic population women #1
    sonographic lucencies #1
    gynecologic oncology reduction #1
    agus pap test #1
    evaluations postpartum #1
    agus pap tests #1
    consecutive pap tests #1
    comprehensive evaluation women #1
    patients agus #1
    endogenous hormonal stimulation #1
    lower cutdown #1
    cervical adenoma malignum #1
    uterus update #1
    ports venous #1
    477 pap tests #1
    cervical carcinomain #1
    city indigent #1
    reduction postoperative narcotic #1
    gynecology female gynecologic #1
    cervical cytology rates #1
    agcus pap test #1
    months hickman #1
    cases pabc #1
    parakeratosis 96 patients #1
    preresidency syndrome #1
    agus pap #1
    replacement emphasis #1
    isolated finding hyperkeratosis #1
    persistence statistical significance #1
    introduction fertilitysparing options #1
    infusaports #1
    dysplasia malignancy #1
    papillomavirus city #1
    current epidemiology review #1
    carcinoma 40 #1
    tissue clomiphene #1

    Key People For Gynecologic Oncology

    Top KOLs in the world
    Pedro T Ramirez
    cervical cancer radical hysterectomy enhanced recovery
    Richard R Barakat
    endometrial cancer fallopian tube residual disease
    Joan L Walker
    gynecologic oncology ovarian cancer fallopian tube
    Robert S Mannel
    gynecologic oncology ovarian cancer fallopian tube
    Brian N Bundy
    gynecologic oncology radiation therapy type 1 diabetes
    William Thomas Creasman
    gynecologic oncology cervical cancer hormone therapy

    JOEL I SOROSKY:Expert Impact

    Concepts for whichJOEL I SOROSKYhas direct influence:Gynecologic oncology,  Cervical cancer,  Ovarian cancer,  Endometrial cancer,  Radiation therapy,  Small bowel,  Social support,  Saphenous vein.


    Concepts related to the work of other authors for whichfor which JOEL I SOROSKY has influence:Endometrial cancer,  Social support,  Radiation therapy,  Magnetic resonance,  Epithelial ovarian,  Quality life,  Uterine cervix.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Abington-Jefferson Health, Philadelphia, PA, United States | Hanjani Institute for Gynecologic Oncology, Asplundh Cancer Pavilion, Abington Hospital-Jefferson Health, 3941 Commerce Avenue, Willow Grove, PA 19090, United States | Hanjani Institute for